Skip to main content
. 2004 Aug 16;143(2):257–268. doi: 10.1038/sj.bjp.0705927

Figure 5.

Figure 5

(a) Western blot of phosphorylated p44/42MAPK and percentage of phosphorylated p44/42MAPK evaluated by densitometry (OD mm−2) of the blots in BAL neutrophils of LPS-treated rats 10 min after 2 μM fMLP addition in the presence of PDE4 inhibitors or MAPK inhibitors (C−=negative control, C+=positive control, W=0.05 nM wortmannin). (b) Western blot of phosphorylated p44/42MAPK and percentage of phosphorylated p44/42MAPK evaluated by densitometry (OD mm−2) of the blots in BAL macrophages of LPS-treated rats at the activation peak induced by 2 μM fMLP in the presence of PDE4 inhibitors or MAPK inhibitors (C−=negative control, C+=positive control, W=0.05 nM wortmannin).